T1	Outcomes 35 70	renal blood flow and renal function
T2	Outcomes 184 228	effects on the treatment of severe hepatitis
T3	Outcomes 317 345	complication of renal damage
T4	Outcomes 349 370	hepatorenal syndrome.
T5	Outcomes 449 554	plasma renin activity (PRA), angiotensin II (AII), aldosterone (ALD), renal blood flow and renal function
T6	Outcomes 929 950	Basic autohemotherapy
T7	Outcomes 1231 1232	.
T8	Outcomes 1233 1293	PRA, AII, ALD, renal blood flow and damage to renal function
T9	Outcomes 1370 1371	.
T10	Outcomes 1372 1386	Survival rates
T11	Outcomes 1472 1475	PRA
T12	Outcomes 1495 1514	ng·ml⁻¹·h⁻¹
T13	Outcomes 1531 1537	17.35)
T14	Outcomes 1624 1640	before treatment
T15	Outcomes 1661 1680	ng·ml⁻¹·h⁻¹
T16	Outcomes 1686 1693	(155.18
T17	Outcomes 1811 1821	days after
T18	Outcomes 1841 1849	(2.02 ±
T19	Outcomes 1856 1875	ng·ml⁻¹·h⁻¹
T20	Outcomes 1928 1951	pg/ml, t = 4.97 - 15.61
T21	Outcomes 2176 2194	23.15) ml/min, t =
T22	Outcomes 2395 2404	group vs.
T23	Outcomes 2405 2407	16
T24	Outcomes 2541 2570	with chronic severe hepatitis
T25	Outcomes 2577 2632	decrease PRA, AII and ALD levels significantly increase
T26	Outcomes 2659 2674	renal damage to
